Compare JG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JG | BOLD |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0M | 36.5M |
| IPO Year | 2018 | 2024 |
| Metric | JG | BOLD |
|---|---|---|
| Price | $6.57 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 2.7K | ★ 140.1K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.85 | $0.96 |
| 52 Week High | $12.74 | $1.71 |
| Indicator | JG | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 54.10 |
| Support Level | $5.98 | $1.12 |
| Resistance Level | $6.97 | $1.55 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 21.43 | 44.00 |
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates in one segment and generates revenues from SAAS Businesses.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.